Recommendations for Prevention of Invasive Pneumococcal Disease
new report from the U.S. Centers for Disease Control
and Prevention (CDC) provides updated recommendations
for prevention of invasive pneumococcal disease (IPD),
which affects a broad spectrum of the U.S. population.
The risk for IPD is highest among individuals who are
immunocompromised, such as those with HIV infection
or asplenia (e.g., sickle cell disease or congenital
or surgical asplenia). Recommendations for revaccination
among persons with immunocompromising conditions remain
unchanged since the report issued in 1997. The indications
for which vaccination is recommended now include smoking
disease from Streptococcus pneumoniae (pneumococcus) is
a major cause of illness and death in the United States, with
an estimated 43,500 cases and 5,000 deaths among persons of all
ages in 2009 (1).
report provides updated recommendations from the Advisory Committee
on Immunization Practices (ACIP) for prevention of invasive pneumococcal
disease (IPD) (i.e., bacteremia, meningitis, or infection of other
normally sterile sites ) through use of the 23-valent pneumococcal
polysaccharide vaccine (PPSV23) among all adults aged ?65 years
and those adults aged 19--64 years with underlying medical conditions
that put them at greater risk for serious pneumococcal infection.
new recommendations include the following changes from 1997 ACIP
recommendations (2): 1) the indications for which PPSV23 vaccination
is recommended now include smoking and asthma, and 2) routine
use of PPSV23 is no longer recommended for Alaska Natives or American
Indians aged <65 years unless they have medical or other indications
recommendations for revaccination with PPSV23 among the adult
patient groups at greatest risk for IPD (i.e., persons with functional
or anatomic asplenia and persons with immunocompromising conditions)
remain unchanged (2).
recommendations for prevention of pneumococcal disease among infants
and youths aged ?18 years using the 13-valent pneumococcal conjugate
vaccine (PCV13) and PPSV23 are published separately (3).
complete report is available on the CDC website at
Nuorti and CG Whitney. Updated Recommendations for Prevention
of Invasive Pneumococcal Disease Among Adults Using the 23-Valent
Pneumococcal Polysaccharide Vaccine (PPSV23). Morbidity and
Mortality Weekly Report. 59(34): 1102-1106 (Free
full text). September 3, 2010.